无创产前基因检测-ag亚洲国际厅

overview

as invasive tests carry a risk of miscarriage of around 0.5%, researchers have long been focused on developing an alternative, highly accurate non-invasive approach. the possibility of diagnosing aneuploidies with a maternal blood test emerged with the discovery of cell free fetal dna (cffdna) in 1997, and in 2008 the first proof-of-principle studies were published showing that non-invasive prenatal testing (nipt) for aneuploidy was possible using next generation sequencing (ngs). ngs technology has advanced rapidly and nipt for down’s syndrome now has detection rates above 99% and false positive rates of 0.1-1%.

uprenatal is a non-invasive prenatal test (nipt) performed on maternal blood to screen pregnancies for the most common fetal chromosome anomalies: trisomy 21 (down syndrome), trisomy 18 (edwards syndrome) and trisomy 13 (patau syndrome).

  • are of advanced maternal age, defined as 35 years of age or older at estimated date of birth(edb);
  • have an abnormal serum screen i.e. fts/ips/mss;
  • have a fetal nuchal translucency (nt) measurement of 3.5mm or greater;
  • have had a previous pregnancy or child with aneuploidy;
  • have fetal congenital anomalies on ultrasound highly suggestive of trisomy 13, 18 or 21.
检测流程 遗传咨询&知情同意 样本采集 dna变异信息检测 遗传信息解读 健康生活指导

guidelines and policy statements

faq:

网站地图